Treatment success and related factors of drug-susceptible and drug-resistant tuberculosis patients in Aceh referral hospital
DOI:
https://doi.org/10.46542/pe.2023.234.289293Keywords:
Bacteriologic, Resistant, Rifampicin, TuberculosisAbstract
Background: Tuberculosis (TB) remains one of the top ten causes of mortality worldwide. It is caused by a single infectious agent, Mycobacterium tuberculosis. Indonesia has the second highest cases globally and has a high burden of rifampicin-resistant (RR-TB). Xpert MTB/RIF has been used as a frontline test to detect RR-TB to improve treatment efficacy.
Objective: This study aims to summarise the bacteriologic conversion rate as the patient’s cured hallmark and related factors among adults confirmed to have pulmonary tuberculosis in a referral hospital in Aceh Province.
Method: The authors assessed 1,244 bacteriologic test results of sputum samples from TB presumptive patients from January 1st to December 31st 2018, in the Clinical Microbiology Laboratory and evaluated bacteriologic conversion.
Result: There were 361 bacteriologic-confirmed TB diagnoses, where 43 (11.9%) were RR-TB. Most TB patients (26.3%) were in close contact with active TB patients.
Conclusion: The study showed TB patients' low follow-up rate and bacteriologic conversion. The high prevalence of TB among close contacts suggests a need for constant surveillance of this high-risk group to end the TB epidemic. Male, young adult, and Aceh Besar residents have observed factors in sputum conversion results.
References
Azarkar, Z., Sharifzadeh, G., Ebrahimzadeh, A., & Olumi, S. (2016). Time to sputum smear conversion in smear-positive pulmonary tuberculosis patients and factors for delayed conversion. Iranian Journal of Medical Sciences, 41(1), 44.
Calderwood, C. J., Wilson, J. P., Fielding, K. L., Harris, R. C., Karat, A. S., Mansukhani, R., & Moore, D. A. (2021). Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis. PLoS medicine, 18(4). https://doi.org/10.1371/journal.pmed.1003566
Cazabon, D., Alsdurf, H., Satyanarayana, S., Nathavitharana, R., Subbaraman, R., Daftary, A., & Pai, M. (2017). Quality of tuberculosis care in high burden countries: The urgent need to address gaps in the care cascade. International Journal of Infectious Diseases, 56, 111-116. https://doi.org/10.1016/j.ijid.2016.10.016
Diacon, A. H., Pym, A., Grobusch, M. P., de los Rios, J. M., Gotuzzo, E., Vasilyeva, I., & Dannemann, B. (2014). Multidrug-resistant tuberculosis and culture conversion with bedaquiline. New England Journal of Medicine, 371(8), 723-732. https://doi.org/10.1056/NEJMoa1313865
Dodd, P. J., Looker, C., Plumb, I. D., Bond, V., Schaap, A., Shanaube, K., & White, R. G. (2016). Age-and sex-specific social contact patterns and incidence of Mycobacterium tuberculosis infection. American Journal of Epidemiology, 183(2), 156-166.
Gebremariam, M. K., Bjune, G. A., & Frich, J. C. (2010). Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: A qualitative study. BMC public health, 10(1), 1-9. https://doi.org/10.1186/1471-2458-10-651
Global tuberculosis report. (2021). Geneva: World Health Organization.
Horne, D. J., Royce, S. E., Gooze, L., Narita, M., Hopewell, P. C., Nahid, P., & Steingart, K. R. (2010). Sputum monitoring during tuberculosis treatment for predicting outcome: Systematic review and meta-analysis. The Lancet infectious diseases, 10(6), 387-394. https://doi.org/10.1016/S1473-3099(10)70071-2
Indonesia Health Ministry. (2022). Dashboard TB Indonesia. https://tbindonesia.or.id/pustaka-tbc/dashboard-tb/
Khawbung, J. L., Nath, D., & Chakraborty, S. (2021). Drug-resistant tuberculosis: a review. Comparative Immunology, Microbiology, and Infectious Diseases, 74, 101574. https://doi.org/10.1016/j.cimid.2020.101574
Marais, B. J. (2016). The global tuberculosis situation and the inexorable rise of drug-resistant disease. Advanced drug delivery reviews, 102, 3-9. https://doi.org/10.1016/j.addr.2016.01.021
Martin, L. J., Roper, M. H., Grandjean, L., Gilman, R. H., Coronel, J., Caviedes, L., & Moore, D. A. (2016). Rationing tests for drug-resistant tuberculosis–Who are we prepared to miss? BMC Medicine, 14(1), 1-9. https://doi.org/10.1186/s12916-016-0576-8
Nhamoyebonde, S., & Leslie, A. (2014). Biological differences between the sexes and susceptibility to tuberculosis. The Journal of infectious diseases, 209(suppl_3), S100-S106. https://doi.org/10.1093/infdis/jiu147
Perrin, F. M., Lipman, M. C., McHugh, T. D., & Gillespie, S. H. (2007). Biomarkers of treatment response in clinical trials of novel antituberculosis agents. The Lancet infectious diseases, 7(7), 481-490. https://doi.org/10.1016/S1473-3099(07)70112-3
Tekalegn, Y., Woldeyohannes, D., Assefa, T., Aman, R., & Sahiledengle, B. (2020). Predictors of time to sputum culture conversion among drug-resistant tuberculosis patients in Oromia region hospitals, Ethiopia. Infection and Drug Resistance, 13, 2547. https://doi.org/10.2147/IDR.S250878
WHO Geneva/IUATLD Paris. International Union Against Tuberculosis and Lung Disease. (1998). Guidelines for surveillance of drug resistance in tuberculosis. The International Journal of Tuberculosis and Lung Disease, 2, 72-89. https://doi.org/10.1016/j.ijmyco.2015.08.002
Wiwing, V., Widysanto, A., & Lugito, N. P. H. (2015). Mycobacterium tuberculosis resistance pattern against first-line drugs in patients from urban areas. International journal of mycobacteriology, 4(4), 302-305. https://doi.org/10.1016/j.ijmyco.2015.08.002
Yates, T. A., & Atkinson, S. H. (2017). Ironing out sex differences in tuberculosis prevalence. The International Journal of Tuberculosis and Lung Disease, 21(5), 483. https://doi.org/10.5588/ijtld.17.0194
Zhang, J., Gou, H., Hu, X., Hu, X., Shang, M., Zhou, J., & Wang, L. (2016). Status of drug-resistant tuberculosis in China: a systematic review and meta-analysis. American Journal of infection control, 44(6), 671-676. https://doi.org/10.1016/j.ajic.2015.12.042
